XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2023
shares
Sep. 30, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Myriam J. Curet, M.D., F.A.C.S. [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On August 11, 2023, Myriam J. Curet, M.D., F.A.C.S., the Company’s Chief Medical Officer, adopted a Rule 10b5-1 trading plan. Ms. Curet’s trading plan provides for the potential sale of up to 27,077 shares of the Company’s common stock, including the potential exercise and sale of up to 21,273 shares of the Company’s common stock subject to stock options, until August 12, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in the Company’s securities.
Name Myriam J. Curet, M.D., F.A.C.S.  
Title Chief Medical Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date August 11, 2023  
Arrangement Duration 367 days  
Myriam J. Curet, M.D., F.A.C.S. Trading Arrangement, Common Stock [Member] | Myriam J. Curet, M.D., F.A.C.S. [Member]    
Trading Arrangements, by Individual    
Aggregate Available 27,077 27,077
Myriam J. Curet, M.D., F.A.C.S. Trading Arrangement, Stock Options [Member] | Myriam J. Curet, M.D., F.A.C.S. [Member]    
Trading Arrangements, by Individual    
Aggregate Available 21,273 21,273